HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ...
Innovhem is proud to be part of the first promotion of the french accelerator for digital health prevention ! BPI France and PariSanté Campus have set up a high-level program to support 20 French companies and strengthen their strategy to accelerate the market launch...
